iTrack™ Canaloplasty to be Featured at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

California, USA, 12 April 2022 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce that the Company's proprietary iTrack™ canaloplasty device will be featured during the official scientific program of the the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, April 22-26, 2022, Washington, D.C.

A summary of the presentations and posters is included below.

Key Glaucoma Presentations:

David Lubeck, MD and Robert Noecker, MD, MBA
"24-Month Evaluation of Endothelial Cell Density and Loss Following Ab-Interno Canaloplasty"
Session: Minimally Invasive Glaucoma Surgery (MIGS) III
Session Date: Sunday, April 24 2022
Session Time: 3:45-3.50pm
Link to Abstract: https://ascrs.confex.com/ascrs/22am/meetingapp.cgi/Paper/81062

James Murphy, MD
"Efficacy of Ab-Interno Canaloplasty Performed with and without GATT Following Previous Glaucoma Laser Treatment"
Session: Minimally Invasive Glaucoma Surgery (MIGS) III
Session Date: Sunday, April 24 2022
Session Time: 3:50-3:55pm
Link to Abstract: https://ascrs.confex.com/ascrs/22am/meetingapp.cgi/Paper/81077

James Murphy, MD
"Efficacy of Ab-Interno Canaloplasty Performed with or without GATT in Cases of Moderate Versus Severe Glaucoma"
Session: Minimally Invasive Glaucoma Surgery (MIGS) III

Session Date: Sunday, April 24 2022
Session Time: 3:58-4:03pm
Link to Abstract: https://ascrs.confex.com/ascrs/22am/meetingapp.cgi/Paper/81078

Shamil Patel, MD
"36-Month Comparison of Clinical and Safety Outcomes of Canaloplasty Performed as a Standalone Procedure or Combined with Cataract Surgery"
Session: Glaucoma- Surgical Outcomes/Comparisons
Session Date: Monday, April 25 2022
Session Time: 8:15-8:20am
Link to Abstract: https://ascrs.confex.com/ascrs/22am/meetingapp.cgi/Paper/81056

Shamil Patel, MD
"3-Year Clinical and Safety Outcomes of Canaloplasty Performed in Controlled and Uncontrolled Glaucoma Patients"
Session: Glaucoma- Surgical Outcomes/Comparisons
Session Date: Monday, April 25 2022
Session Time: 8:20-8:25am
Link to Abstract: https://ascrs.confex.com/ascrs/22am/meetingapp.cgi/Paper/81058

George Reiss, MD and Shamil Patel, MD
"Long-Term Clinical and Safety Outcomes of Canaloplasty Performed across All Grades of Glaucoma Severity"
Session: Glaucoma- Surgical Outcomes/Comparisons
Session Date: Monday, April 25 2022
Session Time: 8:28-8:33am
Link to Abstract: https://ascrs.confex.com/ascrs/22am/meetingapp.cgi/Paper/81059

Mohsain Gill, MD, Mahmoud A. Khaimi, David Murphy, MD, Kai Ding, PhD and Kamram M. Riaz, MD
"Performing Ab-Interno Canaloplasty Post Keratoplasty- 12-month Outcomes"
Session: Minimally Invasive Glaucoma Surgery (MIGS) II
Session Date: Monday, April 25 2022
Session Time: 1:35-1:40pm
Link to Abstract: https://ascrs.confex.com/ascrs/22am/meetingapp.cgi/Paper/80030

Mahmoud A Khaimi, MD
"Ab-Interno Canaloplasty Standalone Versus Combined with Cataract Surgery- 36-month Outcomes in 1000+ eyes"
Session: Minimally Invasive Glaucoma Surgery (MIGS) II
Session Date: Monday, April 25, 2022
Session Time: 1:40-1:45pm
Link to Abstract: https://ascrs.confex.com/ascrs/22am/meetingapp.cgi/Paper/80237

Mahmoud A Khaimi, MD
"Ab-Interno Canaloplasty in Patients with Primary Angle Closure- 12-month Outcomes"
Session: Minimally Invasive Glaucoma Surgery (MIGS) II
Session Date: Monday April 25, 2022
Session Time: 1:45-1:50pm
Link to Abstract: https://ascrs.confex.com/ascrs/22am/meetingapp.cgi/Paper/80238

James Murphy, MD
"Efficacy and Safety Profile of Ab-Interno Canaloplasty Performed with and without GATT – 12-Month Outcomes"
Session: Minimally Invasive Glaucoma Surgery (MIGS) II
Session Date: Monday, April 25 2022
Session Time: 1:50-1:55pm
Link to Abstract: https://ascrs.confex.com/ascrs/22am/meetingapp.cgi/Paper/81075

Nova Eye Medical will also be exhibiting at the ASCRS, **exhibit #757.**

All educational content of the ASCRS/ASOA Annual Meeting is planned by its Program Committee, and ASCRS and ASOA do not endorse, promote, approve, or recommend the use of any products, devices, or services.

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™, a consumable surgical device for the treatment of glaucoma. The Company also manufactures and sells the proprietary Molteno3® glaucoma drainage device for the treatment of severe or complex glaucoma. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit: www.nova-eye.com

---

ABOUT CANALOPLASTY

First introduced in 2008, canaloplasty is a surgical treatment for glaucoma that targets the main sites of outflow resistance in the conventional outflow pathway: the trabecular meshwork, Schlemm's canal, and the distal collector channels. Based on the same principles as angioplasty, a flexible microcatheter is cannulated 360 degrees around Schlemm's canal during the procedure to manually break and remove blockages. Next, viscoelastic fluid is injected into Schlemm's canal as the microcatheter is withdrawn to dilate the distal outflow system and to improve the function of the trabecular meshwork.

Canaloplasty is typically performed using either of the following two surgical techniques:

- Performed via an ab-interno surgical technique, canaloplasty is a highly effective treatment option for cases of mild-moderate glaucoma. It typically reduces intraocular pressure (IOP) to the low teens. It has also been observed to reduce patient dependence on medications. The ab-interno surgical technique is an implant-free, tissue-sparing procedure that preserves future treatment options.

- Performed via an ab-externo surgical technique, canaloplasty is a highly effective treatment option for patients with severe glaucoma that overcomes the risks and discomfort associated with traditional glaucoma surgery. With over 100,000 procedures performed to date, clinical studies show that canaloplasty has an excellent safety profile, with minimal post-operative follow-up, fast recovery time, and infrequent intra-operative and postoperative complications.

ABOUT THE iTRACK™ PORTFOLIO

Nova Eye Medical (formerly iScience Interventional) pioneered the canaloplasty market with the launch of the world's first canaloplasty device, *iTrack*™, in 2008. Since then, more than 100,000 canaloplasty procedures have been performed with the *iTrack*™ device, cementing its role in the treatment of glaucoma both as a standalone procedure and in combination with cataract surgery.

The iTrack™ canaloplasty microcatheter has been cleared for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma. The iTrack™ canaloplasty microcatheter is currently not 510(k) cleared for use with the ab-interno technique in the United States.

For additional information about iTrack™, including safety information, please visit: www.glaucoma-iTrack.com

---